Rhumbline Advisers reduced its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 0.7% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,337,978 shares of the company's stock after selling 23,961 shares during the period. Rhumbline Advisers owned about 0.17% of Kenvue worth $71,266,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Grove Bank & Trust boosted its holdings in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Kenvue during the fourth quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new position in Kenvue during the third quarter worth about $35,000. Fortitude Family Office LLC grew its position in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after buying an additional 1,441 shares during the last quarter. Institutional investors own 97.64% of the company's stock.
Analysts Set New Price Targets
Several research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and cut their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a report on Wednesday, January 15th. Barclays reduced their target price on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. UBS Group decreased their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $23.00.
Read Our Latest Stock Report on KVUE
Kenvue Trading Up 0.5 %
Shares of Kenvue stock traded up $0.11 during trading on Thursday, reaching $22.38. 19,044,773 shares of the stock were exchanged, compared to its average volume of 13,433,218. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock's fifty day moving average is $21.28 and its 200 day moving average is $22.14. The firm has a market cap of $42.90 billion, a price-to-earnings ratio of 42.22, a price-to-earnings-growth ratio of 2.57 and a beta of 1.45. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.66%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's payout ratio is 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
